European Archives - Page 218 of 1177 - European Medical Journal

The Role of the Gut Microbiome in Food Allergies

Dysbiosis, or microbial imbalance, can predispose individuals to allergies, while a balanced gut microbiome fosters immune tolerance.

cancer illustration

Novocure’s Phase III trial shows promise for pancreatic cancer

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.

Non-Invasive Risk Score Predicts Clinical Events in Primary Sclerosing Cholangitis

The study involved 419 patients, aged 18–75, with noncirrhotic PSC, who were randomly assigned to receive either cilofexor or a placebo over 96 weeks.

Nasal Spray Could Transform Alzheimer’s Treatment

Nasal spray drug shows promise in halting Alzheimer’s progression by targeting brain enzyme linked to cognitive decline.

Surgery Outperforms Collagenase Injections for Dupuytren’s Contracture

Limited fasciectomy proves more effective than collagenase injections for improving hand health in patients with Dupuytren’s contracture, new research shows.

Hypertensive Pregnancy Disorders Linked to Higher Heart Attack Risk

Women with a history of hypertensive disorders during pregnancy face a higher risk of early coronary artery disease and myocardial infarction, a new study finds.

Chronic Pain Linked to Cerebrovascular Disease Deaths in Patients with Cancer

A recent study has explored the relationship between chronic pain and the risk of death from cerebrovascular disease in cancer patients…

1 in 20 Adult Outpatients Hospitalised After RSV Diagnosis

Approximately 1 in 20 individuals diagnosed with RSV in outpatient settings were hospitalised within 28 days.

New AGA Guidelines for Treating Moderate-to-Severe Ulcerative Colitis

The American Gastroenterological Association has released a new set of guidelines to assist healthcare providers in the pharmacological management of moderate-to-severe ulcerative colitis.

Long-Term Relief for Children with Severe Atopic Dermatitis

The study demonstrated that baricitinib significantly improved clinical signs of moderate-to-severe atopic dermatitis in children and adolescents at 16 weeks.